Aktive Positionen von Jonathan Hahn
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| Tuteur SA | Direktor/Vorstandsmitglied | 01.01.2013 | - |
| Präsident | 01.01.2013 | - | |
| Corporate Officer/Principal | 01.01.2013 | - | |
| Tuteur SACIFIA | Direktor/Vorstandsmitglied | 01.01.2013 | - |
| Präsident | 01.01.2013 | - |
Karriereverlauf von Jonathan Hahn
Ehemalige bekannte Positionen von Jonathan Hahn
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| FOREST LABORATORIES, INC. | Corporate Officer/Principal | - | - |
| KAMADA LTD. | Direktor/Vorstandsmitglied | 25.03.2010 | - |
Ausbildung von Jonathan Hahn
| University of San Andres | Undergraduate Degree |
| The Leonard N Stern School of Business | Masters Business Admin |
Statistik
International
| Argentinien | 4 |
| Vereinigte Staaten | 3 |
| Israel | 2 |
Operativ
| Director/Board Member | 3 |
| Corporate Officer/Principal | 2 |
| President | 2 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| KAMADA LTD. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
| Tuteur SA | |
Forest Laboratories, Inc.
 Forest Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Forest Laboratories, Inc. is engaged in the development, manufacture, and sale of branded forms of drug products. Its products include Bystolic, which is used to decrease heart rate and myocardial contractility; Daliresp, which is used to reduce the risk of chronic obstructive pulmonary disease exacerbation; Linzess, which is used in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation; and Namenda, which is used in the treatment of moderate to severe dementia. The company was founded in 1954 and is headquartered in New York, NY. | Health Technology |
| Tuteur SACIFIA |
- Börse
- Insiders
- Jonathan Hahn
- Erfahrung
